BRAF and melanoma: The study encompassed both in vitro and in vivo experiments, utilizing BRAF-mutant melanoma cell lines A375 and SK-MEL-28 treated with valsartan alone or in combination with vemurafenib, as well as immunocompromised mice xenografted with A375 cells receiving the same treatment regimens.